Overall, the in vivo drug treatment study further suggests that synergistically inhibiting PI3K and MAPK pathways can significantly inhibit tumor growth in those lapatinib resistant tumors with loss of function mutations of CSK or PTEN. The gene discussed is PIK3CB; the disease is neoplasm.